Biacore Appoints New Senior Vice President of Business & Technology Development

Uppsala, Sweden, May 11, 2005. Biacore International AB (SSE: BCOR) announces today that it has appointed Dr Bjorn Olof Nilsson to the newly created position of Senior Vice President of Business and Technology Development. Dr Nilsson will join Biacore’s Executive Management Team and will take up his position on June 1, 2005. Biacore has appointed Dr Nilsson (born 1956) to this new position to assist it in driving forward both the Company’s near-term and medium-term growth, based on its leading global position in the field of protein interaction analysis. In his new job Dr Nilsson has been tasked with: • Assisting in strengthening Biacore’s customer relations, with particular reference to leading academic centers globally and important pharmaceutical and biotech companies. • Optimizing the Company’s long-term product development activities by ensuring that Biacore’s future products clearly meet the emerging needs of its key academic and industrial customers.. • Assessing business and new technology opportunities for long-term profitable growth. Dr Nilsson has over 20 years experience in the pharmaceutical and biotechnology industry in both commercial and scientific roles and is respected and well connected within the life science industry both in Sweden and globally. Dr Nilsson chairs the Swedish biotechnology organization SwedenBIO. Prior to joining Biacore Dr Nilsson was President and CEO of Karo Bio AB from July 2001. Before assuming his position at Karo Bio, Dr Nilsson was Global Vice President Protein Area R&D and Vice President of R&D Sweden for Amersham Pharmacia Biotech and prior to this he was Director of Biology Research for Pharmacia & Upjohn AB from October 1996 to December 1997. Dr Nilsson also worked at Pharmacia Biopharmaceuticals from 1992 to 1996 where he was Head of Structural Biochemistry. Erik Walldén, President and CEO of Biacore, commenting on today’s announcement, said: “I am delighted to have Björn on board. With him joining we now have a complete and very complementary executive management team in place. I am sure that his wide-ranging scientific and commercial experience will be a tremendous asset as we continue to maximize the potential of Biacore’s leading global position in the field of protein interaction analysis. In addition, with his network of contacts and understanding of cutting edge technologies across the broad life science industry, Björn will allow us to pinpoint the strategic acquisitions that are expected to form an important element of our future growth. ” - End - About Biacore Biacore is a global supplier of analytical systems that improve the productivity of research and development in the life science and pharmaceutical markets. The company's instruments generate unique data on protein interactions, an area of increasing focus in these markets. The data give insights into protein functionality, the role of proteins in normal and diseased states, and the influence of potential drug candidates. Use of Biacore products is well-documented in key areas such as antibody characterization, proteomics, lead optimization and bio-therapeutic development and production. Customers include world renowned life science research centers, all of the leading global pharmaceutical companies and a large number of companies in the emerging biotechnology sector. Biacore is successfully expanding into the food analysis market, providing key manufacturers with ready-to-use solutions for the determination of food quality and safety. The company offers a range of products to meet specific customer needs. All instruments utilize Surface Plasmon Resonance (SPR) technology as the basis for detection and monitoring of protein interactions. Biacore has its own direct sales capability in the world's key markets, United States, Europe, Japan, Australia and a distribution network in Asia-Pacific. The company was created in 1984, is based in Uppsala, Sweden, and is listed on the Stockholm Stock Exchange www.stockholmsborsen.se (SSE:BCOR). For further information, please contact: Erik Walldén, President and CEO +41 79 769 4542 Scientific/Trade Press Enquiries: Sue Cresswell, Market Communication Director +41 (0) 79710 8311